Enhancing Electronic Health Record Data Quality

By Michael Awood

September 6, 2023

Electronic Health Record (EHR) data in biomedical research has seen a significant surge, especially during the COVID-19 pandemic. These rich data records are perfect for complex analyses, including machine learning and artificial intelligence. However, the quality of this data has drawn much concern.

Despite the critical role EHR data plays in healthcare and its frequent use in biomedical research, its quality is often overlooked. This presents a need for a standardised approach to evaluate EHR data quality.

In 1996, Wang and Strong proposed a data quality framework that covered intrinsic, contextual, representational, and accessible data quality. They highlighted that poor data quality could have social and economic impacts. Although their study was not healthcare-specific, their framework focused on the needs of data users, providing a unique perspective.

A 2013 review identified five aspects of EHR data quality – completeness, correctness, concordance, plausibility, and currency. They evaluated these aspects through seven methods, including a gold standard comparison and data element agreement. However, the definitions of these methods and dimensions often overlapped, indicating the need for a more standardised approach. Other data quality frameworks have been suggested, but they differ in their recording and discussion methods. This shows a lack of consensus and adoption.

The development of automated tools for data quality assessment holds the potential to address the data quality challenge. These tools could streamline the process and enhance efficiency. The article suggests that future research should aim at creating tools that improve data integrity and reliability in patient care and research. The potential impact of this work is vast, with implications for disease tracking, patient care, and the advancement of medical science.

It is important that EHRs reflect true and accurate data to minimise potential downstream inefficiencies – due to poor data. This data also feeds into prediction analytics or algorithms for various AI systems, where poor data could result in incorrect analytics and poor outcomes. At present, there are numerous entry points to an EHR due to the multitude of records. Data sources include researchers, medical providers, and increasingly, patients through patient-reported outcome measures (PROMs). Utilising the framework by Wang and Strong could provide a better understanding of data needs, leading to improved health records and health information exchanges (HIEs).

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.